

Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A small-molecule NNMT inhibitor studied across adipocyte, skeletal-muscle, and cancer-stroma preclinical models.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Small molecule (NNMT inhibitor)
Molecular formula
C10H11IN2
Molecular weight
286.11 g/mol
CAS number
42464-96-0
Modification
Quaternary N-methyl quinolinium cation with a 5-amino substituent; commonly supplied as the iodide salt research reagent.
A substrate-site small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT; EC 2.1.1.1), the cytosolic enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide, yielding 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine. The cationic quinolinium ring occupies the nicotinamide substrate-binding pocket; selectivity profiling against related SAM-dependent methyltransferases and NAD+ salvage enzymes has been characterized in vitro.
Lyophilized
Store solid at -20°C, desiccated and protected from light
typically stable ~24 months.
Hygroscopic salt - keep desiccated; protect from light; avoid freeze-thaw of stocks.
Reviews
Frontiers in Pharmacology (2024 review) (2024). Frontiers in Pharmacology
Pissios P. (2017). Trends in Endocrinology & Metabolism
Roberti A, Fernández AF, Fraga MF. (2021). Mol Metab
Reviews
Li JJ, Sun WD, Zhu XJ, et al. (2024). Metabolites
Li XY, Pi YN, Chen Y, Zhu Q, Xia BR. (2022). Front Oncol
Liu JR, Deng ZH, Zhu XJ, et al. (2021). Biomed Res Int
Liang G, Li Y, Lin Y, et al. (2022). Genes Dis
Primary research
Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. (2024). Diabetes, Obesity and Metabolism
Dimet-Wiley AL, et al. (2024). Scientific Reports
Reustle A, Menig L-S, Leuthold P, et al. (2022). Clinical and Translational Medicine
Dimet-Wiley AL, Wu Q, Wiley JT, Eswar A, Neelakantan H, Savidge T, Watowich SJ. (2022). Scientific Reports
Awosemo O, Neelakantan H, Watowich S, Ma J, Wu L, Chow DS, Liang D. (2021). Journal of Pharmaceutical and Biomedical Analysis
Sampson CM, Dimet AL, Neelakantan H, Ogunseye KO, Stevenson HL, Hommel JD, Watowich SJ. (2021). Scientific Reports
J Obstet Gynaecol (2021 in vitro study, author byline unverified) (2021). Journal of Obstetrics and Gynaecology
Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, et al. (2019). Nature
Neelakantan H, Brightwell CR, Graber TG, Maroto R, Wang HYL, McHardy SF, Papaconstantinou J, Fry CS, Watowich SJ. (2019). Biochemical Pharmacology
Neelakantan H, et al. (2018). Biochemical Pharmacology
Neelakantan H, Wang HY, Vance V, Hommel JD, McHardy SF, Watowich SJ. (2017). Journal of Medicinal Chemistry
Kraus D, Yang Q, Kong D, et al. (2014). Nature
Pompei V, Cecati M, Serritelli EN, et al. (2025). Biomolecules
Pozzi V, Molinelli E, Campagna R, et al. (2024). Hum Cell
Kannt A, Rajagopal S, Hallur MS, et al. (2021). Molecules
Also known as: 5-amino-1-methylquinolinium
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| 5-Amino-1MQThis page | Small molecule (NNMT inhibitor) | 286.11 g/mol | 42464-96-0 |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods